Genitourinary Cancer

PV QA 1 - Poster Viewing Q&A 1

SU_26_2260 - PSMA-PET-Based Salvage By Image-Guided Adaptive HDR-Brachytherapy (HDR-IGABT) for Locally Relapsed Prostate Cancer or Stereotactic Radiation Therapy (SRT) for Distant Oligometastatic Progression - One-Year Outcomes of a Prospective Assessment in 35 Patien

Sunday, October 21
1:15 PM - 2:45 PM
Location: Innovation Hub, Exhibit Hall 3

PSMA-PET-Based Salvage By Image-Guided Adaptive HDR-Brachytherapy (HDR-IGABT) for Locally Relapsed Prostate Cancer or Stereotactic Radiation Therapy (SRT) for Distant Oligometastatic Progression – One-Year Outcomes of a Prospective Assessment in 35 Patien
R. Galalae1,2, R. Hepp2, C. Morgenstern2, J. P. Exner2, and G. Schabl2; 1Medical Faculty, Christian-Albrechts-University, Kiel, Germany, 2Evangelical Clinics Gelsenkirchen, Radiotherapy Department, Gelsenkirchen, Germany

Purpose/Objective(s): To analyze prospectively outcomes of salvage HDR-IGABT for locally relapsed radioresistent/recurrent prostate cancer (LR-PC) and SRT for oligometastatic prostate cancer disease (OM-PC).

Materials/Methods: PSMA-PET was used to detect LR-PC and/or OM-PC in patients with rising PSA values following pre-irradiation or radical prostatectomy (RPE). Thirty-five patients were included with detection of 20 local relapses (5 patients after RPE without irradiation, 10 patients externally pre-irradiated with a mean dose of 69 Gy, and 5 patients following HDR monotherapy pre-treated with 3 x 11.5 Gy), 8 patients with OM-PC (6 externally pre-irradiated with a mean dose of 67.15 Gy), and 7 patients without any PSMA-radioligands accumulation. Thus, the detection rate was 80%. Eligible for this analysis were 18 patients with LR-PC irradiated with a salvage HDR-protocol of 3 x 9 Gy (EQD2 alpha/beta 3 >100 Gy), and 7 patients with OM-PC treated with SRT (EQD2 alpha/beta 3 >70 Gy) with a follow-up (FU) >3 months. The acute/chronic toxicity was assessed according to CTCAE classification. The biochemical control was measured by repetitive PSA measurements along with clinical examination incl. ultrasound. In recurrently rising values a new PSMA-PET was performed.

Results: Mean FU was 10 months (3-26 months). Mean iPSA pre-salvage was 3.68 ng/ml. Mean one-year post-salvage PSA was 0.9 ng/ml (local salvage), and 0.05 ng/ml (SRT). The one-year overall and cancer specific survival was 100% for the entire cohort. The one-year biochemical control (BC) according ASTRO/Phoenix definitions was 81.25% for the local salvage and 71.4% for the SRT treatments, respectively. The one-year disease-free survival (DFS) was 88% for the local salvage and 71.4% for the SRT treatments, respectively. In general, the observed acute/chronic toxicity was very low. Local salvage acute toxicity grade 1-2 haematuria/cystitis occurred in weeks 2-4 only, and one patient developed a grade 2-obstruction in week 5. One patient was treated with TURP for grade 3 obstruction at 20 months. Acute/chronic gastrointestinal toxicity was insignificant (one grade 2 proctitis at 6 months). Rectal spacers were implanted prior intervention in 7 patients with local salvage. One patient developed pronounced fatigue. SRT-toxicity was insignificant as well (two patients with fatigue and one patient with grade 3 proctitis in week 3).

Conclusion: The one-year outcomes of PSMA-PET based salvage brachytherapy for locally relapsed radioresistent/recurrent prostate cancer and stereotactic radiotherapy for oligometastatic prostate cancer disease were very promising with very low prospectively measured acute/chronic CTCAE toxicity profiles. Table 1: One-year results for PSMA-PET based salvage HDR-IGABT in locally relapsed prostate cancer and SRT in oligometastatic prostate cancer
RT Method (N) Indication 1-Y OS 1-Y CSS 1-Y BC 1 Y-DFS
HDR-IGABT (N=18) Local relapse 100% 100% 81.25% 88%
SRT (N=7) Oligometastatic disease 100% 100% 71.4% 71.4%

Author Disclosure: R. Galalae: None. R. Hepp: None. C. Morgenstern: None. J. Exner: None. G. Schabl: None.

Send Email for Razvan Galalae


Assets

SU_26_2260 - PSMA-PET-Based Salvage By Image-Guided Adaptive HDR-Brachytherapy (HDR-IGABT) for Locally Relapsed Prostate Cancer or Stereotactic Radiation Therapy (SRT) for Distant Oligometastatic Progression - One-Year Outcomes of a Prospective Assessment in 35 Patien



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for PSMA-PET-Based Salvage By Image-Guided Adaptive HDR-Brachytherapy (HDR-IGABT) for Locally Relapsed Prostate Cancer or Stereotactic Radiation Therapy (SRT) for Distant Oligometastatic Progression - One-Year Outcomes of a Prospective Assessment in 35 Patien